Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand
- 28 August 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (17) , 6819-6843
Abstract
Recently, we have demonstrated that N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) (1) adopts a bitopic pose at one protomer of a dopamine D2 receptor (D2R) dimer to negatively modulate the binding of dopamine at the other protomer. The 1H-indole-2-carboxamide moiety of 1 extends into a secondary pocket between the extracellular ends of TM2 and TM7 within the D2R protomer. To target this putative allosteric site, we generated and characterized fragments that include and extend from the 1H-indole-2-carboxamide moiety of 1. N-Isopropyl-1H-indole-2-carboxamide (3) displayed allosteric pharmacology and sensitivity to mutations of the same residues at the top of TM2 as was observed for 1. Using 3 as an “allosteric lead”, we designed and synthesized an extensive fragment library to generate novel SAR and identify N-butyl-1H-indole-2-carboxamide (11d), which displayed both increased negative cooperativity and affinity for the D2R. These data illustrate that fragmentation of extended compounds can expose fragments with purely allosteric pharmacology.Keywords
Funding Information
- Department of Health, Disability and Ageing (519461, APP1011920, APP1049654, APP1052304)
- Monash University
- National Natural Science Foundation of China (21206086, 21274116, 21374088, 21406122, 31270625)
- Program for New Century Excellent Talents in University (NCET-13-0476)
- Northwestern Polytechnical University (13GH014602)
- Department of Industry, Innovation, Science, Research and Tertiary Education, Australian Government (DP110100687)
This publication has 45 references indexed in Scilit:
- International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric LigandsPharmacological Reviews, 2014
- Reverse Engineering of the Selective Agonist TBPB Unveils Both Orthosteric and Allosteric Modes of Action at the M1 Muscarinic Acetylcholine ReceptorMolecular Pharmacology, 2013
- Bridging the gap: bitopic ligands of G-protein-coupled receptorsTrends in Pharmacological Sciences, 2013
- Molecular Alliance—From Orthosteric and Allosteric Ligands to Dualsteric/Bitopic Agonists at G Protein Coupled ReceptorsAngewandte Chemie International Edition, 2012
- The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein–Coupled ReceptorsAnnual Review of Pharmacology and Toxicology, 2012
- The allosteric vestibule of a seven transmembrane helical receptor controls G-protein couplingNature Communications, 2012
- Hybrid Ortho/Allosteric Ligands for the Adenosine A1ReceptorJournal of Medicinal Chemistry, 2010
- Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivityThe FASEB Journal, 2008
- Structural diversity of G protein-coupled receptors and significance for drug discoveryNature Reviews Drug Discovery, 2008
- A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic ReceptorMolecular Pharmacology, 2007